CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2011 and provided an update on corporate developments.
“The past year was an extraordinary one for ARIAD,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “We advanced our ponatinib and AP26113 development programs, established the leadership team of our commercial operations, elected to retain all global rights to our product candidates with no plans for any future partnerships and raised $258 million in a public offering that we believe was overwhelmingly supported by our shareholders. We now have the resources to become a global oncology company that will discover, develop and commercialize its own targeted therapies for cancer patients with the greatest medical need.”
